Hypothetically, the ability of SGLT-2 inhibitors to prevent both development of HF and HF hospitalizations in patients with prevalent HF [44], linked to multiple mechanisms, including reduced LV loading conditions and decreased arterial stiffness [35, 44–48], could translate into delayed onset of symptoms in AS patients on medical therapy. Here, SLC5A2 is linked to aortic stenosis.